Here's How Moderna Is Ensuring Its Lead in the Coronavirus Vaccine Market

A product that generates about $200,000 in quarterly sales may not sound too exciting. But what if I told you that product was on the market for only two weeks in that quarter? And what if this product was a particular company's first ever to reach commercialization? Now it's probably starting to sound impressive.

As you might have guessed (thanks to the headline of this article), I'm referring to Moderna (NASDAQ:MRNA) and its coronavirus vaccine. Clearly, Moderna investors have reason to cheer.